Larimar Therapeutics, Inc. LRMR 深 沪
等待开盘 06-25 09:30:00 美东时间
3.63
-0.050
-1.36%
华盛通- 最 高3.795
- 今 开3.69
- 成交量 156.88万股
- 最 低 3.61
- 昨 收 3.68
- 总市值 3.77亿
- 52周最高 6.42
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 2.715
- 委 比 -3.77%
- 总股本 1.04亿
- 历史最高 664.32
- 量 比 0.76
- 振 幅 5.03%
- 历史最低 1.53
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9
JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
05-27 21:48
U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys
U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys May 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilent Technologies, Fedex and Synopsys on Wednesday. HIGHLIGHTS * Agilent Technologies Inc A.N : RBC i
05-27 16:06
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
05-18 20:30
Larimar Therapeutics shares are trading lower. The company reported Q1 EPS results.
Larimar Therapeutics shares are trading lower. The company reported Q1 EPS resu...
05-15 01:36
Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses of $(0.46) per share
05-14 19:14
BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million
BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million May 14 (Reuters) - Larimar Therapeutics Q1 income from operations USD -31.117 million. Q1 operating expenses USD 31.117 million Q1 EPS USD -0.31
05-14 19:00
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Larimar Therapeutics reported strong momentum advancing nomlabofusp toward potential approval for Friedreich’s ataxia (FA), with plans to initiate a rolling BLA submission in June 2026. The company published cross-species nonclinical findings supporting skin FXN levels as a surrogate endpoint and received Breakthrough Therapy Designation. Financially, Larimar had $200.4 million in cash as of March 2026, with a cash runway into Q2 2027. Upcoming m...
05-14 11:00
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
